 Nanette Santoro
Concepts (910)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 88 | 2023 | 262 | 17.640 |
Why?
| | Infertility, Female | 44 | 2023 | 94 | 8.730 |
Why?
| | Women's Health | 41 | 2023 | 271 | 6.550 |
Why?
| | Hot Flashes | 31 | 2023 | 72 | 6.450 |
Why?
| | Estrogen Replacement Therapy | 29 | 2023 | 116 | 6.140 |
Why?
| | Follicle Stimulating Hormone | 61 | 2022 | 214 | 5.970 |
Why?
| | Perimenopause | 24 | 2022 | 59 | 5.700 |
Why?
| | Luteinizing Hormone | 54 | 2022 | 169 | 5.340 |
Why?
| | Menstrual Cycle | 33 | 2023 | 109 | 5.240 |
Why?
| | Estradiol | 56 | 2024 | 452 | 5.240 |
Why?
| | Polycystic Ovary Syndrome | 33 | 2022 | 141 | 5.230 |
Why?
| | Endocrinology | 9 | 2023 | 69 | 4.970 |
Why?
| | Postmenopause | 33 | 2020 | 300 | 4.190 |
Why?
| | Anti-Mullerian Hormone | 16 | 2023 | 50 | 4.100 |
Why?
| | Infertility | 13 | 2024 | 47 | 3.970 |
Why?
| | Reproductive Medicine | 8 | 2023 | 15 | 3.790 |
Why?
| | Ovary | 23 | 2024 | 190 | 3.600 |
Why?
| | Estrogens | 22 | 2024 | 315 | 3.350 |
Why?
| | Female | 328 | 2024 | 59913 | 3.110 |
Why?
| | Progesterone | 37 | 2023 | 232 | 3.060 |
Why?
| | Ovulation Induction | 29 | 2022 | 49 | 2.830 |
Why?
| | Primary Ovarian Insufficiency | 13 | 2021 | 30 | 2.820 |
Why?
| | Fertilization in Vitro | 18 | 2024 | 71 | 2.810 |
Why?
| | Androgens | 15 | 2021 | 165 | 2.700 |
Why?
| | Obesity | 29 | 2022 | 2517 | 2.660 |
Why?
| | Metabolic Syndrome | 14 | 2021 | 324 | 2.630 |
Why?
| | Luteal Phase | 16 | 2020 | 41 | 2.590 |
Why?
| | Hormones | 12 | 2021 | 132 | 2.520 |
Why?
| | Humans | 348 | 2024 | 115587 | 2.450 |
Why?
| | Reproduction | 8 | 2022 | 180 | 2.360 |
Why?
| | Fertility | 14 | 2022 | 131 | 2.200 |
Why?
| | Aging | 26 | 2024 | 1631 | 2.140 |
Why?
| | Adult | 181 | 2024 | 30718 | 2.040 |
Why?
| | Endometrium | 15 | 2020 | 59 | 1.980 |
Why?
| | Testosterone | 24 | 2021 | 337 | 1.950 |
Why?
| | Ovulation | 14 | 2018 | 39 | 1.920 |
Why?
| | Live Birth | 20 | 2022 | 48 | 1.890 |
Why?
| | Ovarian Follicle | 10 | 2024 | 61 | 1.870 |
Why?
| | Fertility Agents, Female | 14 | 2022 | 19 | 1.870 |
Why?
| | Menopause, Premature | 4 | 2021 | 8 | 1.860 |
Why?
| | Gonadal Steroid Hormones | 13 | 2024 | 124 | 1.840 |
Why?
| | Cardiovascular Diseases | 22 | 2024 | 1724 | 1.720 |
Why?
| | Estrogens, Conjugated (USP) | 12 | 2023 | 34 | 1.680 |
Why?
| | Hormone Replacement Therapy | 9 | 2022 | 77 | 1.680 |
Why?
| | Sexual Dysfunction, Physiological | 9 | 2018 | 60 | 1.660 |
Why?
| | Quality of Life | 17 | 2023 | 2385 | 1.600 |
Why?
| | Depression | 12 | 2019 | 1145 | 1.590 |
Why?
| | Infertility, Male | 11 | 2022 | 60 | 1.580 |
Why?
| | Carotid Intima-Media Thickness | 10 | 2021 | 65 | 1.500 |
Why?
| | Middle Aged | 116 | 2024 | 26999 | 1.460 |
Why?
| | Pregnancy | 64 | 2024 | 5548 | 1.440 |
Why?
| | Amenorrhea | 12 | 2017 | 27 | 1.390 |
Why?
| | Pregnanediol | 10 | 2020 | 12 | 1.390 |
Why?
| | Biomarkers | 31 | 2022 | 3466 | 1.390 |
Why?
| | Vagina | 3 | 2020 | 148 | 1.390 |
Why?
| | Body Mass Index | 34 | 2022 | 1971 | 1.390 |
Why?
| | Gonadotropin-Releasing Hormone | 16 | 2022 | 193 | 1.380 |
Why?
| | Vasomotor System | 8 | 2021 | 38 | 1.340 |
Why?
| | Pregnancy Rate | 20 | 2022 | 55 | 1.320 |
Why?
| | Vaginal Diseases | 3 | 2020 | 17 | 1.310 |
Why?
| | Estrone | 11 | 2024 | 35 | 1.300 |
Why?
| | Endocrinologists | 3 | 2023 | 12 | 1.300 |
Why?
| | Hypothalamus | 10 | 2014 | 150 | 1.300 |
Why?
| | Premenopause | 13 | 2022 | 103 | 1.260 |
Why?
| | Hormone Antagonists | 2 | 2021 | 38 | 1.240 |
Why?
| | Double-Blind Method | 29 | 2023 | 1660 | 1.230 |
Why?
| | Inhibins | 8 | 2018 | 45 | 1.220 |
Why?
| | Embryo Transfer | 10 | 2024 | 29 | 1.210 |
Why?
| | Atherosclerosis | 6 | 2024 | 341 | 1.190 |
Why?
| | Gynecology | 2 | 2021 | 185 | 1.160 |
Why?
| | Receptors, Neurokinin-3 | 3 | 2023 | 6 | 1.150 |
Why?
| | Endometriosis | 4 | 2022 | 41 | 1.140 |
Why?
| | Anovulation | 7 | 2015 | 8 | 1.120 |
Why?
| | Cryopreservation | 5 | 2024 | 93 | 1.110 |
Why?
| | Hyperlipidemias | 5 | 2022 | 124 | 1.110 |
Why?
| | Uterus | 4 | 2019 | 193 | 1.080 |
Why?
| | Prospective Studies | 42 | 2024 | 6264 | 1.050 |
Why?
| | Sleep Wake Disorders | 6 | 2021 | 233 | 1.050 |
Why?
| | Patient Selection | 7 | 2021 | 654 | 1.030 |
Why?
| | Hyperinsulinism | 3 | 2022 | 103 | 1.020 |
Why?
| | Clomiphene | 9 | 2021 | 15 | 1.020 |
Why?
| | Insulin | 11 | 2022 | 2082 | 1.010 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 49 | 1.000 |
Why?
| | Randomized Controlled Trials as Topic | 19 | 2023 | 1216 | 0.990 |
Why?
| | Mental Health | 2 | 2022 | 571 | 0.970 |
Why?
| | HIV Infections | 17 | 2024 | 2473 | 0.950 |
Why?
| | Sex Hormone-Binding Globulin | 14 | 2020 | 47 | 0.950 |
Why?
| | Biomedical Research | 4 | 2023 | 588 | 0.940 |
Why?
| | Follicle Stimulating Hormone, Human | 3 | 2022 | 11 | 0.930 |
Why?
| | Salpingo-oophorectomy | 1 | 2024 | 11 | 0.920 |
Why?
| | Life Cycle Stages | 1 | 2023 | 31 | 0.910 |
Why?
| | United States | 49 | 2023 | 12295 | 0.900 |
Why?
| | Longitudinal Studies | 25 | 2020 | 2416 | 0.900 |
Why?
| | Menarche | 2 | 2017 | 49 | 0.890 |
Why?
| | Gonadotropins | 5 | 2020 | 37 | 0.870 |
Why?
| | Aromatase | 3 | 2014 | 31 | 0.850 |
Why?
| | Progestins | 4 | 2017 | 75 | 0.850 |
Why?
| | Drug Compounding | 3 | 2021 | 89 | 0.830 |
Why?
| | Ovarian Reserve | 3 | 2020 | 13 | 0.830 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2017 | 197 | 0.830 |
Why?
| | Irritable Mood | 3 | 2018 | 48 | 0.820 |
Why?
| | Sexual Health | 1 | 2023 | 48 | 0.820 |
Why?
| | Lipids | 7 | 2023 | 588 | 0.820 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2021 | 1198 | 0.810 |
Why?
| | Treatment Outcome | 35 | 2023 | 9159 | 0.810 |
Why?
| | Pituitary Gland | 6 | 2021 | 152 | 0.810 |
Why?
| | Sleep Initiation and Maintenance Disorders | 4 | 2018 | 116 | 0.790 |
Why?
| | Age Factors | 22 | 2023 | 2907 | 0.770 |
Why?
| | Corpus Luteum | 7 | 2017 | 19 | 0.770 |
Why?
| | Administration, Cutaneous | 12 | 2023 | 116 | 0.770 |
Why?
| | Hydrocortisone | 4 | 2022 | 273 | 0.760 |
Why?
| | Soybean Oil | 1 | 2021 | 12 | 0.760 |
Why?
| | Embryo, Mammalian | 1 | 2022 | 214 | 0.760 |
Why?
| | Fetal Research | 1 | 2021 | 3 | 0.760 |
Why?
| | Research Subjects | 1 | 2021 | 40 | 0.760 |
Why?
| | Federal Government | 1 | 2021 | 26 | 0.750 |
Why?
| | Bicycling | 1 | 2021 | 74 | 0.750 |
Why?
| | Hand Strength | 1 | 2021 | 97 | 0.740 |
Why?
| | Cross-Sectional Studies | 30 | 2022 | 4435 | 0.740 |
Why?
| | Sleep | 9 | 2021 | 625 | 0.730 |
Why?
| | Adolescent | 47 | 2021 | 17889 | 0.720 |
Why?
| | Symptom Assessment | 2 | 2021 | 121 | 0.720 |
Why?
| | Ultrasonography | 6 | 2018 | 641 | 0.710 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2021 | 151 | 0.710 |
Why?
| | Risk Factors | 46 | 2024 | 8697 | 0.700 |
Why?
| | Reproductive Health | 3 | 2023 | 70 | 0.700 |
Why?
| | Longevity | 1 | 2021 | 136 | 0.700 |
Why?
| | Premature Birth | 3 | 2022 | 278 | 0.690 |
Why?
| | Young Adult | 32 | 2022 | 10470 | 0.680 |
Why?
| | Obstetrics | 1 | 2021 | 161 | 0.680 |
Why?
| | Phospholipids | 1 | 2021 | 202 | 0.670 |
Why?
| | Practice Guidelines as Topic | 3 | 2016 | 1405 | 0.670 |
Why?
| | Hypogonadism | 8 | 2015 | 74 | 0.660 |
Why?
| | Spatial Memory | 1 | 2019 | 17 | 0.650 |
Why?
| | Cohort Studies | 28 | 2023 | 4944 | 0.650 |
Why?
| | Sexuality | 1 | 2018 | 18 | 0.640 |
Why?
| | Hysterosalpingography | 1 | 2018 | 6 | 0.640 |
Why?
| | Hypothalamic Diseases | 3 | 2017 | 17 | 0.630 |
Why?
| | Ovarian Hyperstimulation Syndrome | 3 | 2008 | 6 | 0.630 |
Why?
| | Life Style | 10 | 2024 | 429 | 0.610 |
Why?
| | Insemination, Artificial | 5 | 2022 | 12 | 0.590 |
Why?
| | Heterocyclic Compounds, 2-Ring | 3 | 2023 | 5 | 0.590 |
Why?
| | Substance-Related Disorders | 6 | 2009 | 950 | 0.580 |
Why?
| | Health Surveys | 5 | 2011 | 446 | 0.560 |
Why?
| | Circadian Rhythm | 3 | 2017 | 371 | 0.560 |
Why?
| | Fetus | 1 | 2021 | 702 | 0.560 |
Why?
| | Hypopituitarism | 2 | 2014 | 14 | 0.550 |
Why?
| | Hysterectomy | 5 | 2023 | 118 | 0.540 |
Why?
| | Cognition | 10 | 2022 | 980 | 0.540 |
Why?
| | Overweight | 5 | 2014 | 469 | 0.540 |
Why?
| | Pregnancy Trimester, First | 2 | 2019 | 127 | 0.540 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 269 | 0.530 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2016 | 26 | 0.530 |
Why?
| | Chorionic Gonadotropin | 9 | 2021 | 78 | 0.530 |
Why?
| | Cumulus Cells | 2 | 2015 | 6 | 0.530 |
Why?
| | Adiposity | 4 | 2020 | 468 | 0.530 |
Why?
| | Surveys and Questionnaires | 20 | 2022 | 4665 | 0.520 |
Why?
| | Levonorgestrel | 1 | 2015 | 32 | 0.520 |
Why?
| | Sweating | 4 | 2018 | 23 | 0.510 |
Why?
| | Uterine Hemorrhage | 3 | 2021 | 35 | 0.510 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 414 | 0.510 |
Why?
| | Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.510 |
Why?
| | Azoospermia | 1 | 2015 | 6 | 0.500 |
Why?
| | Abortion, Spontaneous | 6 | 2021 | 92 | 0.500 |
Why?
| | Anxiety | 4 | 2018 | 853 | 0.490 |
Why?
| | Bone Density | 7 | 2011 | 432 | 0.490 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 90 | 0.470 |
Why?
| | Body Composition | 9 | 2024 | 580 | 0.470 |
Why?
| | Pulsatile Flow | 3 | 2011 | 54 | 0.470 |
Why?
| | Vulvodynia | 1 | 2014 | 2 | 0.470 |
Why?
| | Nitriles | 5 | 2015 | 152 | 0.470 |
Why?
| | Granulosa Cells | 4 | 2021 | 29 | 0.470 |
Why?
| | Time Factors | 19 | 2024 | 6165 | 0.460 |
Why?
| | Cross-Over Studies | 4 | 2022 | 434 | 0.460 |
Why?
| | Indoles | 1 | 2016 | 309 | 0.450 |
Why?
| | Triazoles | 5 | 2015 | 132 | 0.450 |
Why?
| | Pregnancy Outcome | 9 | 2021 | 336 | 0.450 |
Why?
| | Blood Proteins | 1 | 2015 | 238 | 0.450 |
Why?
| | Pregnancy, Multiple | 4 | 2015 | 14 | 0.430 |
Why?
| | Osteoporosis | 1 | 2016 | 227 | 0.430 |
Why?
| | Insulin Resistance | 9 | 2023 | 1078 | 0.430 |
Why?
| | Solubility | 2 | 2023 | 226 | 0.420 |
Why?
| | Stress, Psychological | 8 | 2018 | 974 | 0.420 |
Why?
| | Complementary Therapies | 3 | 2022 | 73 | 0.410 |
Why?
| | Parity | 2 | 2011 | 99 | 0.410 |
Why?
| | Male | 62 | 2022 | 55949 | 0.410 |
Why?
| | Follicular Phase | 12 | 2014 | 37 | 0.410 |
Why?
| | Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.410 |
Why?
| | Cell Cycle | 1 | 2015 | 546 | 0.400 |
Why?
| | Prevalence | 13 | 2019 | 2264 | 0.400 |
Why?
| | Prolactin | 4 | 2022 | 95 | 0.400 |
Why?
| | Follow-Up Studies | 16 | 2023 | 4440 | 0.390 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 43 | 0.390 |
Why?
| | Intracranial Thrombosis | 1 | 2011 | 17 | 0.380 |
Why?
| | Weight Gain | 5 | 2020 | 453 | 0.380 |
Why?
| | Menstruation | 9 | 2012 | 35 | 0.380 |
Why?
| | Fallopian Tubes | 3 | 2018 | 29 | 0.380 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2008 | 257 | 0.380 |
Why?
| | Exercise | 3 | 2022 | 1609 | 0.380 |
Why?
| | Endocrine System | 1 | 2011 | 20 | 0.380 |
Why?
| | Thyrotropin | 3 | 2022 | 100 | 0.380 |
Why?
| | Pregnancy, Ectopic | 3 | 2021 | 53 | 0.380 |
Why?
| | Uterine Diseases | 2 | 2007 | 14 | 0.360 |
Why?
| | Coronary Artery Disease | 4 | 2019 | 607 | 0.360 |
Why?
| | Thiadiazoles | 2 | 2020 | 21 | 0.360 |
Why?
| | Methotrexate | 4 | 2021 | 228 | 0.360 |
Why?
| | Logistic Models | 14 | 2015 | 1856 | 0.350 |
Why?
| | Abortifacient Agents, Nonsteroidal | 2 | 2021 | 19 | 0.350 |
Why?
| | Prognosis | 14 | 2020 | 3339 | 0.350 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2021 | 32 | 0.350 |
Why?
| | Activins | 3 | 2005 | 26 | 0.350 |
Why?
| | Watchful Waiting | 2 | 2021 | 57 | 0.340 |
Why?
| | Regression Analysis | 7 | 2020 | 959 | 0.340 |
Why?
| | Odds Ratio | 14 | 2015 | 962 | 0.340 |
Why?
| | Oocyte Donation | 1 | 2009 | 4 | 0.340 |
Why?
| | Multicenter Studies as Topic | 8 | 2022 | 249 | 0.330 |
Why?
| | Vulva | 1 | 2009 | 24 | 0.330 |
Why?
| | Signal Transduction | 3 | 2021 | 4541 | 0.330 |
Why?
| | Trinucleotide Repeats | 1 | 2009 | 24 | 0.330 |
Why?
| | Administration, Oral | 8 | 2020 | 734 | 0.330 |
Why?
| | Breast Neoplasms | 4 | 2022 | 1872 | 0.330 |
Why?
| | Hyperandrogenism | 4 | 2017 | 14 | 0.330 |
Why?
| | Multivariate Analysis | 13 | 2015 | 1440 | 0.320 |
Why?
| | Fertility Agents | 2 | 2020 | 2 | 0.320 |
Why?
| | Luteal Cells | 1 | 2008 | 2 | 0.320 |
Why?
| | Semen | 4 | 2022 | 18 | 0.320 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2009 | 61 | 0.320 |
Why?
| | Ovariectomy | 3 | 2023 | 117 | 0.320 |
Why?
| | Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.320 |
Why?
| | Mentors | 1 | 2010 | 162 | 0.310 |
Why?
| | Adaptation, Psychological | 3 | 2018 | 551 | 0.310 |
Why?
| | Administration, Intravaginal | 2 | 2020 | 20 | 0.310 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 684 | 0.310 |
Why?
| | Carotid Artery Diseases | 2 | 2020 | 58 | 0.310 |
Why?
| | Bone Remodeling | 2 | 2008 | 65 | 0.310 |
Why?
| | Vitamin D Deficiency | 2 | 2021 | 159 | 0.310 |
Why?
| | Aged | 21 | 2023 | 19251 | 0.310 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 53 | 0.310 |
Why?
| | Mood Disorders | 3 | 2015 | 117 | 0.310 |
Why?
| | Risk Assessment | 12 | 2024 | 2987 | 0.300 |
Why?
| | Oocyte Retrieval | 3 | 2015 | 11 | 0.300 |
Why?
| | Incidence | 8 | 2020 | 2335 | 0.300 |
Why?
| | Polyps | 1 | 2007 | 11 | 0.300 |
Why?
| | Metformin | 3 | 2012 | 278 | 0.300 |
Why?
| | Leiomyoma | 2 | 2019 | 45 | 0.300 |
Why?
| | Vitamin D | 3 | 2021 | 341 | 0.290 |
Why?
| | Pericardium | 3 | 2019 | 50 | 0.290 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2023 | 246 | 0.290 |
Why?
| | Virilism | 1 | 2007 | 5 | 0.290 |
Why?
| | Antioxidants | 2 | 2021 | 533 | 0.280 |
Why?
| | Lactation | 1 | 2008 | 149 | 0.280 |
Why?
| | Dehydroepiandrosterone Sulfate | 6 | 2011 | 44 | 0.280 |
Why?
| | Fertilization | 3 | 2022 | 41 | 0.280 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 162 | 0.280 |
Why?
| | Reproductive Techniques | 3 | 2001 | 6 | 0.280 |
Why?
| | Weight Loss | 5 | 2024 | 633 | 0.270 |
Why?
| | Pilot Projects | 5 | 2020 | 1377 | 0.270 |
Why?
| | Affect | 3 | 2018 | 244 | 0.270 |
Why?
| | Cytokines | 3 | 2021 | 1853 | 0.270 |
Why?
| | Metabolome | 1 | 2009 | 287 | 0.270 |
Why?
| | Specimen Handling | 3 | 2018 | 156 | 0.270 |
Why?
| | Inflammation | 3 | 2022 | 2499 | 0.270 |
Why?
| | Attitude to Health | 3 | 2009 | 409 | 0.270 |
Why?
| | Bariatric Surgery | 1 | 2008 | 162 | 0.260 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 309 | 0.260 |
Why?
| | New York City | 6 | 2010 | 74 | 0.260 |
Why?
| | Leuprolide | 4 | 1998 | 20 | 0.260 |
Why?
| | Case-Control Studies | 7 | 2020 | 3022 | 0.260 |
Why?
| | Oxidative Stress | 2 | 2021 | 1093 | 0.250 |
Why?
| | Atrophy | 2 | 2020 | 152 | 0.250 |
Why?
| | Contraceptive Agents, Female | 2 | 2016 | 65 | 0.250 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 503 | 0.250 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3254 | 0.250 |
Why?
| | Socioeconomic Factors | 7 | 2013 | 1086 | 0.250 |
Why?
| | Dehydroepiandrosterone | 5 | 2016 | 49 | 0.240 |
Why?
| | Age of Onset | 3 | 2017 | 450 | 0.240 |
Why?
| | Recovery of Function | 1 | 2008 | 577 | 0.240 |
Why?
| | Follistatin | 1 | 2004 | 12 | 0.240 |
Why?
| | C-Reactive Protein | 4 | 2022 | 364 | 0.240 |
Why?
| | Biology | 2 | 2023 | 78 | 0.240 |
Why?
| | Academic Medical Centers | 4 | 2021 | 414 | 0.240 |
Why?
| | Vascular Calcification | 2 | 2019 | 107 | 0.240 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 941 | 0.230 |
Why?
| | Adipose Tissue | 3 | 2019 | 555 | 0.230 |
Why?
| | Embryo Culture Techniques | 1 | 2024 | 12 | 0.230 |
Why?
| | Skin Aging | 2 | 2016 | 19 | 0.230 |
Why?
| | Insulin-Like Growth Factor I | 4 | 2022 | 281 | 0.230 |
Why?
| | Child | 22 | 2023 | 18488 | 0.220 |
Why?
| | Oligomenorrhea | 2 | 2014 | 6 | 0.220 |
Why?
| | Fractures, Bone | 2 | 2008 | 372 | 0.220 |
Why?
| | Bone Resorption | 2 | 2015 | 74 | 0.220 |
Why?
| | Drug Therapy, Combination | 5 | 2018 | 962 | 0.220 |
Why?
| | Endometrial Hyperplasia | 1 | 2023 | 15 | 0.220 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 553 | 0.220 |
Why?
| | Reference Values | 8 | 2020 | 744 | 0.220 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 8 | 0.220 |
Why?
| | Carotid Stenosis | 1 | 2024 | 78 | 0.220 |
Why?
| | Dyspareunia | 2 | 2016 | 8 | 0.220 |
Why?
| | Interleukin-6 | 2 | 2022 | 677 | 0.220 |
Why?
| | Diabetes Mellitus | 3 | 2023 | 906 | 0.210 |
Why?
| | Dilatation and Curettage | 2 | 2021 | 10 | 0.210 |
Why?
| | Anti-HIV Agents | 2 | 2005 | 669 | 0.210 |
Why?
| | Referral and Consultation | 3 | 2016 | 646 | 0.210 |
Why?
| | Asymptomatic Diseases | 3 | 2018 | 77 | 0.210 |
Why?
| | Animals | 14 | 2023 | 32102 | 0.210 |
Why?
| | Reimbursement Mechanisms | 2 | 2001 | 78 | 0.200 |
Why?
| | Simvastatin | 1 | 2002 | 59 | 0.200 |
Why?
| | Cuba | 3 | 2010 | 11 | 0.200 |
Why?
| | Goals | 1 | 2023 | 158 | 0.200 |
Why?
| | Central America | 3 | 2010 | 16 | 0.200 |
Why?
| | Human Growth Hormone | 1 | 2022 | 38 | 0.200 |
Why?
| | Puerto Rico | 3 | 2010 | 52 | 0.200 |
Why?
| | Smoking | 6 | 2015 | 1457 | 0.200 |
Why?
| | South America | 3 | 2010 | 53 | 0.200 |
Why?
| | Washington | 1 | 2022 | 134 | 0.200 |
Why?
| | Germ Cells | 1 | 2022 | 61 | 0.200 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 73 | 0.200 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 30 | 0.200 |
Why?
| | Health Behavior | 1 | 2007 | 707 | 0.190 |
Why?
| | Semen Analysis | 4 | 2022 | 10 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3069 | 0.190 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 27 | 0.190 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 28 | 0.190 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 151 | 0.190 |
Why?
| | Emulsions | 1 | 2021 | 44 | 0.190 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 30 | 0.190 |
Why?
| | Sexual Behavior | 3 | 2016 | 440 | 0.190 |
Why?
| | Cell Proliferation | 2 | 2009 | 2194 | 0.180 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 207 | 0.180 |
Why?
| | Linear Models | 7 | 2019 | 776 | 0.180 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1048 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 242 | 0.180 |
Why?
| | Thinness | 1 | 2021 | 87 | 0.180 |
Why?
| | Drug Combinations | 3 | 2016 | 289 | 0.180 |
Why?
| | Genetic Fitness | 1 | 2021 | 54 | 0.180 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 92 | 0.180 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 113 | 0.180 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 181 | 0.180 |
Why?
| | Dominican Republic | 2 | 2010 | 18 | 0.180 |
Why?
| | Spermatozoa | 3 | 2022 | 84 | 0.180 |
Why?
| | RNA, Messenger | 6 | 2011 | 2574 | 0.180 |
Why?
| | Obesity, Abdominal | 2 | 2022 | 38 | 0.180 |
Why?
| | Vitamins | 1 | 2021 | 151 | 0.180 |
Why?
| | Coitus | 2 | 2022 | 27 | 0.180 |
Why?
| | Choice Behavior | 1 | 2021 | 159 | 0.170 |
Why?
| | Lipoproteins, HDL | 3 | 2015 | 76 | 0.170 |
Why?
| | Electronics | 1 | 2000 | 68 | 0.170 |
Why?
| | Ethics, Medical | 1 | 2000 | 70 | 0.170 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 162 | 0.170 |
Why?
| | Down-Regulation | 5 | 2019 | 601 | 0.170 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 165 | 0.170 |
Why?
| | Puberty | 2 | 2019 | 137 | 0.170 |
Why?
| | Growth Hormone | 2 | 2022 | 99 | 0.170 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2011 | 36 | 0.170 |
Why?
| | Leptin | 3 | 2022 | 211 | 0.170 |
Why?
| | Gene Expression | 3 | 2021 | 1435 | 0.170 |
Why?
| | Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.170 |
Why?
| | Surgeons | 1 | 2023 | 238 | 0.170 |
Why?
| | Adiponectin | 3 | 2022 | 214 | 0.170 |
Why?
| | Erectile Dysfunction | 1 | 2019 | 38 | 0.170 |
Why?
| | Cell Nucleolus | 2 | 2010 | 17 | 0.170 |
Why?
| | Acculturation | 2 | 2010 | 52 | 0.160 |
Why?
| | Spermatogenesis | 1 | 2019 | 52 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 794 | 0.160 |
Why?
| | Decidua | 1 | 2019 | 23 | 0.160 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 1 | 2019 | 24 | 0.160 |
Why?
| | Sperm Count | 4 | 2022 | 16 | 0.160 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 12 | 0.160 |
Why?
| | Carotid Arteries | 1 | 2020 | 183 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.160 |
Why?
| | Allostasis | 1 | 2018 | 13 | 0.160 |
Why?
| | Ovarian Diseases | 3 | 1993 | 12 | 0.160 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 38 | 0.160 |
Why?
| | Waist Circumference | 5 | 2022 | 122 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 373 | 0.160 |
Why?
| | Infant, Newborn | 9 | 2024 | 5077 | 0.150 |
Why?
| | Decision Support Techniques | 1 | 2022 | 353 | 0.150 |
Why?
| | Precision Medicine | 1 | 2022 | 344 | 0.150 |
Why?
| | Adrenal Glands | 1 | 1998 | 72 | 0.150 |
Why?
| | Genitalia | 1 | 2018 | 28 | 0.150 |
Why?
| | Child Behavior | 1 | 2020 | 218 | 0.150 |
Why?
| | Periodicity | 8 | 2016 | 56 | 0.150 |
Why?
| | Placebos | 2 | 2015 | 198 | 0.150 |
Why?
| | Keratin-18 | 1 | 2017 | 10 | 0.150 |
Why?
| | Religion | 1 | 2018 | 66 | 0.150 |
Why?
| | Comorbidity | 5 | 2014 | 1473 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2018 | 234 | 0.140 |
Why?
| | Brachial Artery | 1 | 2018 | 173 | 0.140 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 20 | 0.140 |
Why?
| | Phytotherapy | 1 | 2017 | 66 | 0.140 |
Why?
| | Disease Progression | 4 | 2020 | 2418 | 0.140 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2017 | 27 | 0.140 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 746 | 0.140 |
Why?
| | Models, Biological | 5 | 2016 | 1646 | 0.140 |
Why?
| | Body Weight | 4 | 2015 | 867 | 0.140 |
Why?
| | Regional Blood Flow | 1 | 2018 | 414 | 0.140 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 115 | 0.140 |
Why?
| | Receptors, Leptin | 2 | 2013 | 24 | 0.140 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 191 | 0.140 |
Why?
| | Antidepressive Agents | 1 | 2018 | 195 | 0.140 |
Why?
| | Microbiota | 1 | 2024 | 652 | 0.140 |
Why?
| | Retrospective Studies | 12 | 2024 | 12608 | 0.140 |
Why?
| | Heart | 1 | 2020 | 608 | 0.130 |
Why?
| | Vaginal Creams, Foams, and Jellies | 1 | 2016 | 6 | 0.130 |
Why?
| | Orgasm | 1 | 2016 | 6 | 0.130 |
Why?
| | Uterine Neoplasms | 1 | 2017 | 73 | 0.130 |
Why?
| | Infant | 15 | 2024 | 7979 | 0.130 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2016 | 29 | 0.130 |
Why?
| | Oxytocics | 1 | 2016 | 15 | 0.130 |
Why?
| | Societies, Scientific | 1 | 2016 | 47 | 0.130 |
Why?
| | Child Development | 1 | 2020 | 389 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1536 | 0.130 |
Why?
| | Health Status | 3 | 2023 | 728 | 0.130 |
Why?
| | Fetal Growth Retardation | 2 | 2019 | 466 | 0.130 |
Why?
| | Endocrine System Diseases | 1 | 2016 | 32 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1361 | 0.130 |
Why?
| | Causality | 2 | 2014 | 106 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1217 | 0.130 |
Why?
| | Fluoroimmunoassay | 2 | 1999 | 3 | 0.130 |
Why?
| | Confidence Intervals | 4 | 2011 | 309 | 0.130 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 347 | 0.130 |
Why?
| | Oxytocin | 1 | 2016 | 45 | 0.130 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 36 | 0.130 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 89 | 0.130 |
Why?
| | Hirsutism | 2 | 2017 | 10 | 0.130 |
Why?
| | Societies, Medical | 3 | 2017 | 684 | 0.130 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2015 | 25 | 0.130 |
Why?
| | Body Constitution | 3 | 2004 | 47 | 0.130 |
Why?
| | Vasodilation | 1 | 2018 | 412 | 0.130 |
Why?
| | Mobility Limitation | 1 | 2015 | 60 | 0.130 |
Why?
| | Stress, Physiological | 1 | 2018 | 399 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.130 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.120 |
Why?
| | Air Pollution | 1 | 2017 | 172 | 0.120 |
Why?
| | Migraine Disorders | 1 | 2016 | 83 | 0.120 |
Why?
| | Limit of Detection | 1 | 2015 | 55 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 476 | 0.120 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 64 | 0.120 |
Why?
| | Antibodies, Bacterial | 1 | 2015 | 119 | 0.120 |
Why?
| | Depressive Disorder, Major | 1 | 2018 | 304 | 0.120 |
Why?
| | Chlamydia Infections | 1 | 2015 | 65 | 0.120 |
Why?
| | Survival Analysis | 4 | 2014 | 1219 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2021 | 805 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 173 | 0.120 |
Why?
| | Contraindications | 1 | 2014 | 86 | 0.120 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 282 | 0.120 |
Why?
| | Physical Fitness | 1 | 2015 | 179 | 0.120 |
Why?
| | Immunoglobulin G | 2 | 2015 | 781 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 78 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 1805 | 0.120 |
Why?
| | Laparoscopy | 1 | 2018 | 400 | 0.120 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 16 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6417 | 0.120 |
Why?
| | Creatinine | 3 | 2022 | 430 | 0.120 |
Why?
| | Sperm Motility | 3 | 2022 | 26 | 0.110 |
Why?
| | Fatigue | 1 | 2015 | 296 | 0.110 |
Why?
| | Child, Preschool | 15 | 2020 | 9133 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 317 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1137 | 0.110 |
Why?
| | Oocytes | 2 | 2011 | 171 | 0.110 |
Why?
| | Bone Marrow Transplantation | 4 | 1999 | 239 | 0.110 |
Why?
| | Range of Motion, Articular | 1 | 2015 | 354 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2015 | 465 | 0.110 |
Why?
| | Liver | 3 | 2023 | 1690 | 0.110 |
Why?
| | Muscle Strength | 1 | 2015 | 275 | 0.110 |
Why?
| | Autoimmunity | 1 | 1999 | 822 | 0.110 |
Why?
| | Methadone | 2 | 2011 | 77 | 0.110 |
Why?
| | Rats | 3 | 2019 | 5034 | 0.110 |
Why?
| | Anxiety Disorders | 1 | 2015 | 310 | 0.110 |
Why?
| | Heart Rate | 1 | 2016 | 701 | 0.100 |
Why?
| | Chi-Square Distribution | 4 | 2015 | 499 | 0.100 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.100 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 724 | 0.100 |
Why?
| | Epithelial Cells | 2 | 2009 | 961 | 0.100 |
Why?
| | Heart Diseases | 1 | 2015 | 330 | 0.100 |
Why?
| | China | 4 | 2011 | 163 | 0.100 |
Why?
| | Varicocele | 1 | 2011 | 10 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2011 | 13 | 0.100 |
Why?
| | Skin | 1 | 2016 | 662 | 0.100 |
Why?
| | Tissue Banks | 1 | 2011 | 18 | 0.100 |
Why?
| | Receptors, Somatomedin | 1 | 2011 | 3 | 0.100 |
Why?
| | Receptors, Glucagon | 1 | 2011 | 23 | 0.100 |
Why?
| | Somatomedins | 1 | 2011 | 29 | 0.100 |
Why?
| | Glucagon | 1 | 2011 | 93 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2015 | 519 | 0.100 |
Why?
| | Pregnancy Complications | 2 | 2015 | 430 | 0.100 |
Why?
| | Receptor, trkA | 1 | 2011 | 16 | 0.100 |
Why?
| | Narcotics | 1 | 2011 | 45 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2353 | 0.100 |
Why?
| | Siblings | 2 | 2009 | 223 | 0.090 |
Why?
| | Algorithms | 3 | 2011 | 1490 | 0.090 |
Why?
| | Actigraphy | 3 | 2017 | 73 | 0.090 |
Why?
| | Autoantibodies | 1 | 1999 | 1360 | 0.090 |
Why?
| | Pelvic Organ Prolapse | 1 | 2011 | 40 | 0.090 |
Why?
| | Glucose | 2 | 2007 | 904 | 0.090 |
Why?
| | CD4 Lymphocyte Count | 3 | 2006 | 257 | 0.090 |
Why?
| | Protease Inhibitors | 1 | 2011 | 101 | 0.090 |
Why?
| | Skin Physiological Phenomena | 1 | 2010 | 26 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 492 | 0.090 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2010 | 7 | 0.090 |
Why?
| | Japan | 3 | 2011 | 88 | 0.090 |
Why?
| | Superovulation | 3 | 2012 | 8 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2011 | 148 | 0.090 |
Why?
| | Hip Fractures | 1 | 2011 | 75 | 0.090 |
Why?
| | Decision Trees | 1 | 2010 | 81 | 0.090 |
Why?
| | Environment | 2 | 2003 | 337 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 350 | 0.090 |
Why?
| | Blood Glucose | 5 | 2019 | 1824 | 0.090 |
Why?
| | Career Mobility | 1 | 2010 | 64 | 0.090 |
Why?
| | Proteomics | 1 | 2015 | 859 | 0.090 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 39 | 0.080 |
Why?
| | Lithium Chloride | 1 | 2009 | 11 | 0.080 |
Why?
| | Comprehension | 1 | 2011 | 158 | 0.080 |
Why?
| | Health Promotion | 1 | 2015 | 693 | 0.080 |
Why?
| | Quality Control | 2 | 2000 | 147 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 209 | 0.080 |
Why?
| | Memory | 1 | 2011 | 211 | 0.080 |
Why?
| | Blastocyst | 1 | 2009 | 43 | 0.080 |
Why?
| | Glucocorticoids | 1 | 1993 | 552 | 0.080 |
Why?
| | HIV Seropositivity | 2 | 2011 | 110 | 0.080 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 14 | 0.080 |
Why?
| | Perception | 1 | 2011 | 315 | 0.080 |
Why?
| | Sleep Apnea Syndromes | 1 | 2009 | 74 | 0.080 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 395 | 0.080 |
Why?
| | Vaginitis | 1 | 2008 | 2 | 0.080 |
Why?
| | Nuclear Pore | 1 | 2008 | 14 | 0.080 |
Why?
| | Birth Weight | 2 | 2024 | 438 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1870 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2008 | 23 | 0.080 |
Why?
| | Embryo Implantation | 1 | 2008 | 23 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2015 | 725 | 0.080 |
Why?
| | Coronary Disease | 2 | 2012 | 348 | 0.080 |
Why?
| | Uterine Prolapse | 1 | 2008 | 14 | 0.080 |
Why?
| | Social Class | 1 | 2009 | 210 | 0.080 |
Why?
| | Infant, Low Birth Weight | 2 | 2019 | 125 | 0.080 |
Why?
| | Androstenedione | 2 | 1999 | 10 | 0.080 |
Why?
| | Analysis of Variance | 4 | 2019 | 1227 | 0.080 |
Why?
| | Anthropometry | 1 | 2008 | 181 | 0.070 |
Why?
| | Self Report | 3 | 2018 | 698 | 0.070 |
Why?
| | Neoplasms | 2 | 1999 | 2118 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 636 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2011 | 386 | 0.070 |
Why?
| | Combined Modality Therapy | 5 | 2021 | 1127 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 342 | 0.070 |
Why?
| | Skin Absorption | 1 | 2007 | 13 | 0.070 |
Why?
| | Cultural Characteristics | 1 | 2007 | 59 | 0.070 |
Why?
| | Research Design | 2 | 2011 | 946 | 0.070 |
Why?
| | Tissue Distribution | 1 | 2007 | 324 | 0.070 |
Why?
| | Receptors, Steroid | 1 | 2007 | 52 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 585 | 0.070 |
Why?
| | Tissue Donors | 1 | 2009 | 331 | 0.070 |
Why?
| | Administration, Topical | 1 | 2007 | 137 | 0.070 |
Why?
| | Asparaginase | 3 | 2001 | 29 | 0.070 |
Why?
| | Proteins | 3 | 1989 | 920 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 535 | 0.070 |
Why?
| | Relaxin | 2 | 1998 | 15 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2009 | 449 | 0.070 |
Why?
| | Age Distribution | 2 | 2004 | 341 | 0.070 |
Why?
| | Spouses | 1 | 2007 | 84 | 0.070 |
Why?
| | Gonadal Hormones | 1 | 2005 | 6 | 0.070 |
Why?
| | Phosphorylation | 2 | 2021 | 1571 | 0.070 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 71 | 0.060 |
Why?
| | Preoptic Area | 1 | 2005 | 6 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 395 | 0.060 |
Why?
| | Inhibin-beta Subunits | 1 | 2005 | 5 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2014 | 1002 | 0.060 |
Why?
| | Maternal Age | 2 | 2022 | 117 | 0.060 |
Why?
| | Phenotype | 3 | 2018 | 2829 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Internet | 2 | 2015 | 602 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2009 | 971 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2005 | 36 | 0.060 |
Why?
| | Nuclear Proteins | 3 | 2022 | 594 | 0.060 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 235 | 0.060 |
Why?
| | Blastomeres | 1 | 2004 | 12 | 0.060 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 221 | 0.060 |
Why?
| | Sex Characteristics | 3 | 2019 | 641 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 485 | 0.060 |
Why?
| | Vulnerable Populations | 1 | 2005 | 138 | 0.060 |
Why?
| | Mass Screening | 1 | 2011 | 1024 | 0.060 |
Why?
| | Infusions, Intravenous | 3 | 1994 | 374 | 0.060 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 97 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1087 | 0.060 |
Why?
| | Bone Marrow | 1 | 2005 | 249 | 0.060 |
Why?
| | Apoptosis | 2 | 2017 | 2377 | 0.060 |
Why?
| | Central Nervous System | 1 | 2005 | 239 | 0.060 |
Why?
| | Mutation | 2 | 2009 | 3364 | 0.060 |
Why?
| | Glutamic Acid | 1 | 2005 | 213 | 0.060 |
Why?
| | Fetal Macrosomia | 1 | 2024 | 58 | 0.060 |
Why?
| | Minority Groups | 1 | 2005 | 230 | 0.060 |
Why?
| | MicroRNAs | 1 | 2009 | 607 | 0.060 |
Why?
| | Contraceptives, Oral | 1 | 2003 | 25 | 0.050 |
Why?
| | Elasticity | 2 | 2016 | 194 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 107 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 29 | 0.050 |
Why?
| | Melphalan | 2 | 1999 | 29 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 930 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
| | Remission Induction | 4 | 2009 | 240 | 0.050 |
Why?
| | Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
| | Whole-Body Irradiation | 2 | 1999 | 72 | 0.050 |
Why?
| | alpha-Amylases | 1 | 2022 | 16 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2392 | 0.050 |
Why?
| | Thyroid Hormones | 1 | 2022 | 53 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2004 | 372 | 0.050 |
Why?
| | Snoring | 1 | 2021 | 12 | 0.050 |
Why?
| | Blood Pressure | 3 | 2017 | 1537 | 0.050 |
Why?
| | Hypertension | 1 | 2010 | 1064 | 0.050 |
Why?
| | Breast | 1 | 2022 | 138 | 0.050 |
Why?
| | Preconception Care | 1 | 2022 | 31 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 23 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2022 | 81 | 0.050 |
Why?
| | Computers | 2 | 2000 | 60 | 0.050 |
Why?
| | Maternal-Child Nursing | 1 | 2001 | 10 | 0.050 |
Why?
| | Prevotella | 1 | 2021 | 12 | 0.050 |
Why?
| | Nursing Methodology Research | 1 | 2001 | 43 | 0.050 |
Why?
| | Canada | 1 | 2022 | 335 | 0.050 |
Why?
| | Grief | 1 | 2001 | 35 | 0.050 |
Why?
| | Open Reading Frames | 1 | 2021 | 116 | 0.050 |
Why?
| | Gestational Age | 1 | 2024 | 757 | 0.050 |
Why?
| | X Chromosome | 1 | 2001 | 47 | 0.050 |
Why?
| | Anger | 1 | 2001 | 55 | 0.050 |
Why?
| | Pulmonary Blastoma | 1 | 2000 | 7 | 0.050 |
Why?
| | Body Surface Area | 1 | 2020 | 27 | 0.050 |
Why?
| | Heparin | 1 | 2022 | 227 | 0.050 |
Why?
| | Radiography | 2 | 2014 | 826 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2018 | 2800 | 0.050 |
Why?
| | Pleural Neoplasms | 1 | 2000 | 18 | 0.050 |
Why?
| | Insemination | 1 | 2020 | 1 | 0.050 |
Why?
| | Illinois | 1 | 2020 | 37 | 0.050 |
Why?
| | Gestures | 1 | 2020 | 3 | 0.050 |
Why?
| | Chicago | 1 | 2020 | 45 | 0.050 |
Why?
| | Paper | 1 | 2000 | 8 | 0.050 |
Why?
| | Blood Volume | 1 | 2020 | 56 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2651 | 0.040 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 1999 | 7 | 0.040 |
Why?
| | Personal Autonomy | 1 | 2000 | 39 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 815 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 1736 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 235 | 0.040 |
Why?
| | Observer Variation | 1 | 2000 | 297 | 0.040 |
Why?
| | Thrombin | 1 | 2000 | 141 | 0.040 |
Why?
| | Focus Groups | 1 | 2021 | 393 | 0.040 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 1999 | 68 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 759 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 47 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 390 | 0.040 |
Why?
| | Triglycerides | 2 | 2017 | 473 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1718 | 0.040 |
Why?
| | Diet | 2 | 2023 | 1072 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 273 | 0.040 |
Why?
| | Neurons | 1 | 2007 | 1298 | 0.040 |
Why?
| | Gene Deletion | 1 | 2001 | 355 | 0.040 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
| | Educational Status | 2 | 2012 | 413 | 0.040 |
Why?
| | Chromosome Breakage | 1 | 1999 | 21 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1999 | 43 | 0.040 |
Why?
| | Chromosome Inversion | 1 | 1999 | 17 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 401 | 0.040 |
Why?
| | Pregnant Women | 1 | 2000 | 132 | 0.040 |
Why?
| | Needs Assessment | 1 | 2001 | 318 | 0.040 |
Why?
| | Insurance, Health | 1 | 2001 | 246 | 0.040 |
Why?
| | Italy | 3 | 2009 | 92 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 489 | 0.040 |
Why?
| | Hyperthyroidism | 1 | 2018 | 26 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 194 | 0.040 |
Why?
| | Injections, Intravenous | 2 | 1990 | 204 | 0.040 |
Why?
| | Microinjections | 1 | 1998 | 78 | 0.040 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 6 | 0.040 |
Why?
| | Organ Size | 2 | 2010 | 434 | 0.040 |
Why?
| | Glucuronates | 1 | 2017 | 4 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 124 | 0.040 |
Why?
| | Islets of Langerhans | 1 | 2004 | 729 | 0.040 |
Why?
| | Conservative Treatment | 1 | 2018 | 29 | 0.040 |
Why?
| | Public Health | 1 | 2022 | 438 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2021 | 458 | 0.040 |
Why?
| | Cholesterol | 1 | 2019 | 369 | 0.040 |
Why?
| | Transaminases | 1 | 2017 | 25 | 0.040 |
Why?
| | Thrombosis | 1 | 2000 | 302 | 0.040 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 10 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2578 | 0.040 |
Why?
| | Immunologic Tests | 1 | 1997 | 16 | 0.040 |
Why?
| | Disease-Free Survival | 4 | 2001 | 621 | 0.040 |
Why?
| | Mice | 4 | 2021 | 15052 | 0.040 |
Why?
| | Pregnancy Tests | 1 | 2017 | 7 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 65 | 0.040 |
Why?
| | Vehicle Emissions | 1 | 2017 | 48 | 0.040 |
Why?
| | Biopsy | 1 | 2000 | 1056 | 0.040 |
Why?
| | Biological Assay | 1 | 2017 | 114 | 0.040 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 34 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2022 | 715 | 0.030 |
Why?
| | Genes | 1 | 1997 | 224 | 0.030 |
Why?
| | Molecular Weight | 3 | 2013 | 329 | 0.030 |
Why?
| | Qualitative Research | 1 | 2021 | 971 | 0.030 |
Why?
| | Transdermal Patch | 1 | 2016 | 15 | 0.030 |
Why?
| | Hepatitis C | 2 | 2011 | 229 | 0.030 |
Why?
| | Hyperprolactinemia | 1 | 2016 | 4 | 0.030 |
Why?
| | Alcohol Drinking | 2 | 2012 | 648 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2001 | 576 | 0.030 |
Why?
| | Galvanic Skin Response | 1 | 2016 | 26 | 0.030 |
Why?
| | Goiter | 1 | 1996 | 3 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 362 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 2 | 2008 | 99 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 478 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 736 | 0.030 |
Why?
| | Catheters, Indwelling | 2 | 1993 | 79 | 0.030 |
Why?
| | Serologic Tests | 1 | 2015 | 51 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1334 | 0.030 |
Why?
| | Hypothyroidism | 1 | 1996 | 65 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1996 | 130 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 390 | 0.030 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1995 | 35 | 0.030 |
Why?
| | Registries | 2 | 2020 | 1770 | 0.030 |
Why?
| | Cranial Irradiation | 2 | 2009 | 66 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1265 | 0.030 |
Why?
| | Genetic Markers | 2 | 2011 | 325 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 174 | 0.030 |
Why?
| | Cyclosporine | 1 | 1995 | 169 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 926 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1999 | 675 | 0.030 |
Why?
| | Vincristine | 3 | 2001 | 96 | 0.030 |
Why?
| | Deafness | 1 | 1996 | 78 | 0.030 |
Why?
| | Certolizumab Pegol | 1 | 2014 | 3 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1357 | 0.030 |
Why?
| | Etanercept | 1 | 2014 | 51 | 0.030 |
Why?
| | Air Pollutants | 1 | 2017 | 246 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 44 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 178 | 0.030 |
Why?
| | Freezing | 1 | 1994 | 85 | 0.030 |
Why?
| | Glycerol | 1 | 1994 | 86 | 0.030 |
Why?
| | Drug Stability | 1 | 1994 | 152 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 94 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 69 | 0.030 |
Why?
| | Anions | 1 | 2013 | 31 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2014 | 139 | 0.030 |
Why?
| | Medical Records | 1 | 2014 | 157 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 795 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2013 | 139 | 0.030 |
Why?
| | Electrocardiography | 1 | 2016 | 560 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1997 | 701 | 0.030 |
Why?
| | Anal Canal | 1 | 1993 | 83 | 0.030 |
Why?
| | Cell Survival | 2 | 2007 | 1024 | 0.030 |
Why?
| | Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 136 | 0.030 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 122 | 0.030 |
Why?
| | Tea | 1 | 2012 | 10 | 0.030 |
Why?
| | Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.030 |
Why?
| | Postoperative Complications | 2 | 2001 | 2161 | 0.030 |
Why?
| | Coffee | 1 | 2012 | 11 | 0.030 |
Why?
| | Pituitary Gland, Anterior | 1 | 2011 | 41 | 0.020 |
Why?
| | Alcoholic Beverages | 1 | 2012 | 17 | 0.020 |
Why?
| | Oogenesis | 1 | 2011 | 25 | 0.020 |
Why?
| | Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
| | Rectocele | 1 | 2011 | 3 | 0.020 |
Why?
| | Women | 1 | 2012 | 51 | 0.020 |
Why?
| | Placentation | 1 | 2011 | 40 | 0.020 |
Why?
| | Fetal Death | 1 | 2011 | 49 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Ulna Fractures | 1 | 2011 | 13 | 0.020 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2011 | 15 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 180 | 0.020 |
Why?
| | Nerve Growth Factor | 1 | 2011 | 27 | 0.020 |
Why?
| | Colon | 1 | 1993 | 234 | 0.020 |
Why?
| | Receptor, trkB | 1 | 2011 | 28 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 252 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2010 | 14 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2010 | 30 | 0.020 |
Why?
| | Radius Fractures | 1 | 2011 | 56 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 163 | 0.020 |
Why?
| | Informed Consent | 1 | 2011 | 161 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 106 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 117 | 0.020 |
Why?
| | Survival Rate | 2 | 2009 | 1650 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 1 | 0.020 |
Why?
| | Proinsulin | 1 | 2010 | 49 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2011 | 78 | 0.020 |
Why?
| | Daunorubicin | 2 | 2001 | 24 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2001 | 1893 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 299 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 201 | 0.020 |
Why?
| | Hematology | 1 | 2009 | 13 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4113 | 0.020 |
Why?
| | Herpes Zoster | 1 | 2014 | 333 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1993 | 478 | 0.020 |
Why?
| | Infusion Pumps | 1 | 1989 | 32 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2009 | 6 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 667 | 0.020 |
Why?
| | Culture Techniques | 1 | 1989 | 80 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 60 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 101 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2009 | 61 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 576 | 0.020 |
Why?
| | Polysomnography | 1 | 2009 | 135 | 0.020 |
Why?
| | Prednisone | 2 | 2001 | 232 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 77 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 187 | 0.020 |
Why?
| | Safety | 1 | 1990 | 298 | 0.020 |
Why?
| | West Indies | 1 | 2008 | 4 | 0.020 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 3 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 2008 | 18 | 0.020 |
Why?
| | Hyperhidrosis | 1 | 2008 | 5 | 0.020 |
Why?
| | RANK Ligand | 1 | 2008 | 26 | 0.020 |
Why?
| | Menorrhagia | 1 | 2008 | 14 | 0.020 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 39 | 0.020 |
Why?
| | Papio | 1 | 2008 | 96 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2262 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1598 | 0.020 |
Why?
| | Pelvic Floor | 1 | 2008 | 24 | 0.020 |
Why?
| | Medical Oncology | 1 | 2009 | 230 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2000 | 2207 | 0.020 |
Why?
| | Transplantation, Autologous | 2 | 1999 | 173 | 0.020 |
Why?
| | Collagen Type I | 1 | 2008 | 110 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 144 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 398 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2007 | 44 | 0.020 |
Why?
| | Isoenzymes | 1 | 2008 | 285 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 139 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 645 | 0.020 |
Why?
| | Transplantation Conditioning | 2 | 1999 | 150 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2008 | 220 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 133 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2010 | 199 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 931 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 919 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2000 | 621 | 0.020 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 52 | 0.020 |
Why?
| | New York | 1 | 2006 | 109 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 820 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 305 | 0.020 |
Why?
| | HIV-1 | 1 | 1991 | 771 | 0.020 |
Why?
| | Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.020 |
Why?
| | Body Fluids | 1 | 1986 | 58 | 0.020 |
Why?
| | Placenta | 1 | 2011 | 624 | 0.020 |
Why?
| | Microdialysis | 1 | 2005 | 50 | 0.020 |
Why?
| | Communication | 1 | 2011 | 750 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2604 | 0.020 |
Why?
| | Stroke | 1 | 2014 | 1016 | 0.020 |
Why?
| | Urban Population | 1 | 2008 | 405 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2007 | 304 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2005 | 105 | 0.020 |
Why?
| | Genomics | 1 | 2009 | 645 | 0.020 |
Why?
| | Demography | 1 | 2005 | 261 | 0.010 |
Why?
| | Life Change Events | 1 | 2005 | 135 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2006 | 296 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2005 | 344 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Interviews as Topic | 1 | 2005 | 596 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 864 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 250 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1569 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4773 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2005 | 396 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 3914 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1103 | 0.010 |
Why?
| | Estrus | 1 | 2001 | 12 | 0.010 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 13 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2000 | 57 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 118 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 186 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1147 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 337 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2000 | 277 | 0.010 |
Why?
| | Transplants | 1 | 1999 | 37 | 0.010 |
Why?
| | Consanguinity | 1 | 1999 | 47 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2001 | 248 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
| | Thioguanine | 1 | 1998 | 19 | 0.010 |
Why?
| | Leucovorin | 1 | 1998 | 42 | 0.010 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 1998 | 38 | 0.010 |
Why?
| | Cytarabine | 1 | 1998 | 52 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1998 | 66 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 1998 | 77 | 0.010 |
Why?
| | Chromosome Aberrations | 1 | 1998 | 134 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1998 | 218 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 297 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 77 | 0.010 |
Why?
| | Doxorubicin | 1 | 1998 | 290 | 0.010 |
Why?
| | Dexamethasone | 1 | 1998 | 316 | 0.010 |
Why?
| | Introns | 1 | 1997 | 226 | 0.010 |
Why?
| | Exons | 1 | 1997 | 300 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 312 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 523 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1997 | 372 | 0.010 |
Why?
| | Risk | 1 | 1998 | 819 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 339 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1996 | 126 | 0.010 |
Why?
| | Drug Resistance | 1 | 1995 | 162 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 952 | 0.010 |
Why?
| | Liver Diseases | 1 | 1996 | 263 | 0.010 |
Why?
| | Colostomy | 1 | 1993 | 26 | 0.010 |
Why?
| | Testis | 1 | 1994 | 134 | 0.010 |
Why?
| | Base Sequence | 1 | 1997 | 2114 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1993 | 140 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2000 | 2125 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1997 | 2790 | 0.010 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1991 | 13 | 0.010 |
Why?
| | Sarcoma, Kaposi | 1 | 1991 | 69 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1310 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 525 | 0.010 |
Why?
| | Feedback | 1 | 1990 | 148 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 224 | 0.010 |
Why?
| | Equipment Contamination | 1 | 1989 | 54 | 0.010 |
Why?
| | Forearm | 1 | 1989 | 114 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1991 | 521 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1989 | 222 | 0.000 |
Why?
| | Organ Culture Techniques | 1 | 1987 | 143 | 0.000 |
Why?
| | Isoelectric Point | 1 | 1986 | 22 | 0.000 |
Why?
| | Hemoglobins | 1 | 1986 | 312 | 0.000 |
Why?
| | Bacteria | 1 | 1989 | 729 | 0.000 |
Why?
|
|
Santoro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|